| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42d3020ad67c717f34d32e1448c74281 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-34 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7c32ac0e4e410b985a4f4a3817c8ae4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ad603bdafab6d6f588ce5cea44a2309
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ecd228991843accbd44c35632d5fe52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_657901eba1904c179a464b5417576260
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09cac824e9fb1196a8573a21720efb50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7feab419300c157335557ddba3978fbf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae803ff1ade0857d47ec808241dac91c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_391ebaf7c64f67484dde73bcac3b8ec0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60f15191cab417c5511bfb1add41306b |
| publicationDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019215175-A1 |
| titleOfInvention |
Oligonucleotides for modulating myh7 expression |
| abstract |
The present invention relates to antisense oligonucleotides that are capable of modulating expression of MYH7 in a target cell. The oligonucleotides hybridize to MYH7 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of hypertrophic cardiomyopathy using the oligonucleotide. |
| priorityDate |
2018-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |